# Liraglutide-bolus vs Glargine-bolus Therapy in Overweight/Obese Type 2 Diabetes Patients (LiraGooD)

> **NCT03087032** · PHASE4 · RECRUITING · sponsor: **The First Affiliated Hospital of Xiamen University** · enrollment: 164 (estimated)

## Conditions studied

- Type 2 Diabetes Patients
- Overweight and Obesity
- Hyperglycaemia (Diabetic)

## Interventions

- **DRUG:** Liraglutide
- **DRUG:** insulin glargine

## Key facts

- **NCT ID:** NCT03087032
- **Lead sponsor:** The First Affiliated Hospital of Xiamen University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2019-01-10
- **Primary completion:** 2025-01-15
- **Final completion:** 2025-02-10
- **Target enrollment:** 164 (ESTIMATED)
- **Last updated:** 2025-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03087032

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03087032, "Liraglutide-bolus vs Glargine-bolus Therapy in Overweight/Obese Type 2 Diabetes Patients (LiraGooD)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03087032. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*